Nektar Therapeutics (NKTR) Q3 2024 earnings summary

Executive summary

• Advanced immunology and inflammation pipeline with REZPEG (rezpegaldesleukin) phase II-B studies for atopic dermatitis and alopecia areata, both on track for 2025 data readouts.

• Announced sale of Huntsville manufacturing facility for $90M ($70M cash, $20M equity), expected to close by December 2, 2024, to strengthen financial position and extend cash runway.

• Published and presented promising clinical and preclinical data for REZPEG and NKTR-255 in dermatology and oncology indications.

• Progressed preclinical programs NKTR-0165 (TNFR2 agonist antibody) and NKTR-422 (PEG-CSF1), with IND-enabling studies underway.

• Restructuring in 2022 and 2023 led to workforce reductions and focus on core R&D programs.

Financial highlights

• Q3 2024 revenue was $24.1M, flat year-over-year; nine-month revenue rose to $69.3M.

• Q3 2024 net loss was $37.1M ($0.18/share), improved from $45.8M in Q3 2023; nine-month net loss narrowed to $126.2M.

• Cash and investments totaled $249M at September 30, 2024, down from $329.4M at year-end 2023.

• Sale of facility to add $90M ($70M cash, $20M equity), extending cash runway into Q4 2026.

• R&D expense was $35M in Q3 2024; full-year R&D guidance $120M–$130M.

Outlook and guidance

• Cash runway projected through Q4 2026, covering key clinical milestones.

• Topline data from phase II-B REZPEG studies in atopic dermatitis expected in H1 2025, alopecia areata in H2 2025.

• Full-year 2024 revenue guidance $90M–$95M; R&D expense $120M–$130M; G&A $75M–$80M.

• At least one early-stage program (NKTR-0165 or NKTR-0166) planned to enter the clinic in 2025.

• Anticipated $40M–$45M gain from facility sale in Q4 2024, with no tax liability.